Results 231 to 240 of about 4,919,522 (294)

Latent Class Analysis of eHealth Literacy in Patients with Acute Coronary Syndrome: Associations with Secondary Prevention Medication Adherence and Care Dependency. [PDF]

Pak J Med Sci
He M, Ye R, Chen L, Pan A.
europepmc   +1 more source

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

Arthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K. de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P. Denton, Madelon C. Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source

Commentary - genetic susceptibility as a risk enhancer in secondary prevention: Contextualizing the CAD polygenic risk score. [PDF]

Am J Prev Cardiol
Perlman M, Liu C, Mehta A.
europepmc   +1 more source

Cost-effectiveness of early inclisiran for the secondary prevention of cardiovascular disease in Aboriginal and Torres Strait Islander Australians: A Markov modelling analysis. [PDF]

Int J Cardiol Cardiovasc Risk Prev
Hargovan S, Hunt N, Kostakis H, Chow CK.
europepmc   +1 more source

Goal Attainment Rate in Secondary Prevention in Taiwan - A Chang Gung Research Database Study. [PDF]

Acta Cardiol Sin
Chen TY, Wu CC, Chen YT, Hou BY, Cheng CI.   +4 more
europepmc   +1 more source

Benefits of Implantable Cardioverter-Defibrillator for Secondary Prevention in Patients With Organic Heart Disease. [PDF]

Ann Noninvasive Electrocardiol
Akagawa R, Otsuki S, Sakurazawa M, Kato A, Furuse H, Suzuki N, Ikami Y, Hasegawa Y, Chinushi M, Inomata T.   +9 more
europepmc   +1 more source

Cognitive screening biases in a secondary prevention Alzheimer's disease clinical trial. [PDF]

Alzheimers Dement
Sai I, Grill JD, Younes K, Winer JR, Cody KA, Sperling R, Mormino EC, Young CB.   +7 more
europepmc   +1 more source